Recent News

By Category: Countermeasures

WHO | Experimental Ebola vaccines

WorldHealthOrganization- The WHO has announced that they have been assessing the status of work to test and eventually license two candidate Ebola vaccines. The two candidate vaccines have clinical-grade vials available for phase 1 pre-licensure clinical trials.

U.S. Ebola case: 80 monitored in Dallas

CNN- Health officials are monitoring not only the people the Dallas Ebola patient had contact with while he was contagious and not isolated, but also dozens of people that they subsequently contacted. Eighty people — the patient’s contacts, plus people with whom they had contact — are now being monitored for Ebola in the Dallas  Read More »

Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections

TheNewEnglandJournalofMedicine- Report by the W.H.O. on the  clinical and epidemiological characteristics of the Ebola epidemic in Guinea, Liberia, Nigeria, and Sierra Leone during the first 9 months of the epidemic (as of September, 14, Senegal had reported only a single case). The report furthermore documents trends in the epidemic thus far and projects expected case numbers  Read More »

Ebola Crisis: Obama Says World Falling Short in Response

WallStreetJournal- President Barack Obama, during a high-level United Nations meeting on the Ebola outbreak,  criticized the international response to the epidemic in West Africa as falling short of what is needed to combat a crisis “spreading at alarming speed.” Specifically, Mr. Obama said institutions like the U.N. need to move faster, and more countries need to contribute  Read More »

Elusys Announces Results from Anthrax Anti-Toxin Trials

GlobalBiodefense- Elusys Therapeutics, Inc. this week announced it has completed three Phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204), an anti-toxin in development for the treatment of inhalation anthrax. Data from these studies support the safety and tolerability of the antitoxin when administered intravenously (IV) at the intended therapeutic dose.